Addex Therapeutics Ltd.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No enriched coverage for $ADXN in the last 7 days.
No SEC Form 4 filings for $ADXN in the last 30 days.
See all $ADXN insider activity →Addex Therapeutics (APE) announced that its 20%-owned spin-out, Neurosterix, completed Phase 1 studies of NTX-253 and plans to advance it into Phase 2 trials for schizophrenia.
Addex Therapeutics (APE) appointed Jean-Philippe Rocher to its executive management team as Head of Pharmaceutical Development, while Mikhail Kalinichev left his role as Head of Translational Science. The changes aim to advance the company's clinical-ready programs. According to AI Analyst, significant catalysts could include trial initiations, positive data, or partnering milestones under the new leadership.
Addex (ADXN) reported a H1 2026 net loss of CHF 3.5M, with cash reserves of CHF 767K. It raised USD 2.8M in capital and regained rights to its GABAB PAM portfolio. The company expects NTX-253 to complete Phase 1 trials by Q4 2026 and is preparing dipraglurant for Phase 2 trials in post-stroke recovery. Management expressed uncertainty about the company's ability to continue as a going concern.
Recent ADXN coverage spans insider activity, earnings and financial news.
Addex Therapeutics (APE) announced that its 20%-owned spin-out, Neurosterix, completed Phase 1 studies of NTX-253 and plans to advance it into Phase 2 trials for schizophrenia.
Addex Therapeutics (APE) appointed Jean-Philippe Rocher to its executive management team as Head of Pharmaceutical Development, while Mikhail Kalinichev left his role as Head of Translational Science. The changes aim to advance the company's clinical-ready programs. According to AI Analyst, significant catalysts could include trial initiations, positive data, or partnering milestones under the new leadership.
The earnings release shows continued losses but extended liquidity, which may temper downside pressure.
Earnings miss and low cash balance suggest downward pressure on the stock.
Q1 loss deepens and cash runway shortens, but the ATM raise provides liquidity into Q3 2027.
AlphAI scores every news story that mentions ADXN with an AI model for sentiment and relevance, and aggregates insider trades from Addex Therapeutics Ltd.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Addex Therapeutics (APE) announced that its 20%-owned spin-out, Neurosterix, completed Phase 1 studies of NTX-253 and plans to advance it into Phase 2 trials for schizophrenia.
1 min readAddex Therapeutics (APE) appointed Jean-Philippe Rocher to its executive management team as Head of Pharmaceutical Development, while Mikhail Kalinichev left his role as Head of Translational Science. The changes aim to advance the company's clinical-ready programs. According to AI Analyst, significant catalysts could include trial initiations, positive data, or partnering milestones under the new leadership.
1 min readAddex (ADXN) reported a H1 2026 net loss of CHF 3.5M, with cash reserves of CHF 767K. It raised USD 2.8M in capital and regained rights to its GABAB PAM portfolio. The company expects NTX-253 to complete Phase 1 trials by Q4 2026 and is preparing dipraglurant for Phase 2 trials in post-stroke recovery. Management expressed uncertainty about the company's ability to continue as a going concern.
2 min readAddex Therapeutics Ltd. (ADXN) furnished an SEC Form 6-K — earnings release. Exhibit 99.3 PRESS RELEASE Addex Therapeutics Reports 2026 Half-Year Results and Provides Corporate Update Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, September 28, 2026 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical co
2 min readAddex Therapeutics (ADXN) will report Q2 2026 results on September 28, 2026. Q1 2026 saw a net loss of CHF 1.71 million, with R&D and admin expenses down. Neurosterix, a spin-out, is advancing NTX-253 for schizophrenia. ADXN raised $2.8 million in August 2026, extending cash runway. Q2 2025 had a net loss of CHF 1.84 million. ADXN stock is at $3.45.
2 min readKalinichev Mikhail (HEAD OF TRANSLATIONAL SCIENCE) sold (to issuer) 306,765 shares of Addex Therapeutics Ltd. (ADXN) on 2026-09-02.
1 min readNunn Jason Raleigh sold (to issuer) 219,561 shares of Addex Therapeutics Ltd. (ADXN) on 2026-09-02.
1 min readMills Roger (CHIEF MEDICAL OFFICER) sold (to issuer) 392,837 shares of Addex Therapeutics Ltd. (ADXN) on 2026-09-02.
1 min readManke Isaac sold (to issuer) 219,561 shares of Addex Therapeutics Ltd. (ADXN) on 2026-09-02.
1 min readLawton Vincent Michael sold (to issuer) 2,507,487 shares of Addex Therapeutics Ltd. (ADXN) on 2026-09-02.
1 min read
